Lab-in-the-Loop: reclaiming the 50% of scientific time lost to data

Webinar: Lab-in-the-Loop: reclaiming the 50% of scientific time lost to data
Date:
Time:

Reserve your spot today!

When data lands ready, QC runs in real time, and AI agents participate in the discovery loop itself - research time goes back to science.

49%

3/5

of biopharma scientists’ time spent on manual data work

Industry survey, 2022

life science leaders who believe their organization has solved this bottleneck

McKinsey

PhDs are doing data entry. AI pilots stall before they influence decisions. Compounds get nominated from runs that should have been repeated. The hard part was never the models, it is everything that has to happen before and after them: QC, formatting, handoffs between instruments and data systems, and the absence of a closed loop between experiments and inference.

This session looks at what changes when the lab produces AI-ready data by design, and when orchestration agents start operating within that loop rather than sitting at the edge of it.

What you will learn

  • Where the 49% actually goes, and which parts are structural versus solvable with today’s infrastructure.
  • How agentic AI fits inside the discovery loop: orchestrators, knowledge graphs, and the human-in-the-loop pattern that works at production scale.
  • The architecture beneath the iceberg, what scientists see versus what has to exist for a closed-loop lab to function reproducibly.
  • Real failure modes: why most lab automation projects do not close the loop, and what separates the ones that do.

Who should attend

  • Heads of Computational Biology, Digital R&D, Data Science, and Lab Automation at pharma and biotech organizations.
  • Scientists and data architects responsible for turning instrument output into decisions.
  • Anyone whose AI pilots have produced interesting POCs that have not made it into regular R&D workflows.

Speakers

Both speakers have built and deployed agentic lab systems inside pharma programs. The session is structured around what they have seen work – and what fails before it reaches production.

Jan Majta, PhD

Director of AI Solutions, Ardigen
Jan Majta is Director of AI Solutions at Ardigen, where he helps biotech and pharma companies apply AI and computational biology to drug discovery and development. He has contributed to over 50 projects ranging from early-stage biotech startups to top pharma, working alongside teams of bioinformaticians, software engineers, and AI developers. With degrees in biotechnology and bioinformatics, and over ten years of industry experience, Jan focuses on translating complex scientific challenges into practical solutions building bridges between drug discovery professionals and dry lab technical teams.

Sergiusz Wesołowski, PhD

Sergiusz is a Lead Data Scientist at Ardigen specializing in knowledge graphs, graph machine learning, and explainable AI for biomedical applications. He focuses on designing AI-driven systems for semantic data integration, metadata harmonization, and decision support across complex life science workflows. With over a decade of experience spanning pharma, biotech, and startups, his work bridges advanced machine learning with real-world scientific data challenges across genomics, EHRs, and large-scale knowledge systems.

Don’t want to miss our webinars? Subscribe to our newsletter and stay up to date.

You might be also interested in:

Blog cover for Ardigen publication on ARDisplay-I and MHC ligand identification in Molecular & Cellular Proteomics
New publication in MCP: Improving MHC ligand identification with machine learning and optimized isolation
Fluorescence microscopy image of cells stained with multiple Cell Painting dyes showing cellular organelles in green, blue, and pink, overlaid with Ardigen brand graphic elements indicating phenomics data in durg discovery
End to End Data-to-Decision Journey for AI-Driven Phenomics in Drug Discovery
Abstract network visualization representing AI-driven integration of biological data and knowledge graphs for target identification in drug discovery.
Target Identification: From Poor Data to Quality Predictions
Abstract data streams representing data sourcing in pharmaceutical research and AI drug discovery
What Are Common Data Sourcing Patterns in Pharmaceutical Research (part 3)

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!